Tributary Capital Management, LLC Intercept Pharmaceuticals, Inc. Transaction History

Tributary Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Oct 13, 2020	SELL	$39.09 - $53.44 $625,440 - $855,040	-16,000 Closed	0 $0
Q2 2020 Jul 20, 2020	SELL	$46.7 - $92.04 $28,020 - $55,224	-600 Reduced 3.61%	16,000 $767,000
Q1 2020 Apr 14, 2020	BUY	$48.35 - $118.68 $203,553 - $499,642	4,210 Added 33.98%	16,600 $1.05 Million
Q4 2019 Jan 16, 2020	BUY	$57.36 - $124.1 $389,474 - $842,639	6,790 Added 121.25%	12,390 $1.54 Million
Q3 2019 Oct 15, 2019	SELL	$58.69 - $80.46 $410,830 - $563,220	-7,000 Reduced 55.56%	5,600 $372,000
Q2 2019 Jul 11, 2019	SELL	$77.77 - $120.68 $62,216 - $96,544	-800 Reduced 5.97%	12,600 $1 Million
Q4 2018 Jan 23, 2019	BUY	$85.79 - $126.46 $120,106 - $177,044	1,400 Added 11.67%	13,400 $1.35 Million
Q3 2018 Oct 16, 2018	BUY	$88.49 - $127.55 $265,470 - $382,650	3,000 Added 33.33%	12,000 $1.52 Million
Q2 2018 Jul 25, 2018	BUY	$60.0 - $85.67 $540,000 - $771,030	9,000 New	9,000 $755,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Tributary Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Tributary Capital Management, LLC with notifications on news.